allogeneic peripheral blood and bone marrow stem cell transplantation for chronic myelogenous leukemia: a single center study

Allogeneic peripheral blood and bone marrow stem cell transplantation for chronic myelogenous leukemia: single center study from Iran.

Allogeneic peripheral blood stem cell transplantation as an alternative to allogeneic bone marrow transplantation.

BMT, including 1) rapid hematopoietic engraftment, 2) less requirement for blood transfusion, antibiotic therapy and hospitalization days, and 3) avoidance of.risks and discomfort associated with general anesthesia for collecting hematopoietic stem cells (2). Taking these advantages into consideration, the use of PBSCwas applied for syngeneic and allogeneic transplantation in the early 1990' s....

Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase.

Eight patients with Ph1-positive chronic myelogenous leukemia (CML) in chronic or accelerated phase received high-dose cyclophosphamide, total body irradiation, and bone marrow transplantation from an HLA-identical sibling donor. All patients had prompt engraftment and achieved complete hematologic remission. Six patients remain alive and in continuous remission with a normal bone marrow karyot...

Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation.

Peripheral blood stem cells (PBSCs) and bone marrow (BM) hematopoietic stem cells represent therapeutic alternatives in allogeneic hematopoietic cell transplantation. Randomized controlled trials and an individual patient data meta-analysis (IPDMA) have demonstrated a decreased risk of disease relapse and an increased risk of acute and chronic graft-versus-host disease (aGVHD, cGVHD) in patient...

Aspergillus pancarditis following bone marrow transplantation for chronic myelogenous leukemia.

A 34-year-old man with chronic myelogenous leukemia developed hemoptysis, pain in the left side of the chest, and a systolic heart murmur eight weeks following an allogeneic bone marrow transplant. His clinical status deteriorated, and he died ten weeks after transplantation. Autopsy revealed unsuspected disseminated aspergillosis, including the unusual finding of Aspergillus pancarditis and pe...

Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia.

Sixteen patients with chronic myelogenous leukemia (CML) underwent allogeneic bone marrow transplantation (BMT) when they presented with or developed objective signs suggesting acceleration of disease. Patients have been followed for a median of 515 days (range 216-806 days). Seven patients are alive from 319 to 732 days (median 538 days). Four patients are in complete remission 501-732 days af...